{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:05Z","timestamp":1790655065468,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejim.2021.12.027","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T08:35:37Z","timestamp":1641458137000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Real world comparison of spironolactone and eplerenone in patients with heart failure"],"prefix":"10.1016","volume":"97","author":[{"given":"Patricia","family":"Pardo-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bouzas-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Couto-Mall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Paniagua-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sagastagoitia-Fornie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Prada-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almenar-Bonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"V\u00e1zquez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda G.","family":"Crespo-Leiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.12.027_bib0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.12.027_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.12.027_bib0003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.12.027_bib0004","first-page":"ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"Mc Donagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.12.027_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2021.12.027_bib0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2021.12.027_bib0007","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2021.12.027_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ejim.2021.12.027_bib0009","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00380-018-1250-1","article-title":"Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure","volume":"34","author":"Yamamoto","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ejim.2021.12.027_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.12.027_bib0011","doi-asserted-by":"crossref","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Meth"},{"key":"10.1016\/j.ejim.2021.12.027_bib0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ejhf.1364","article-title":"Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years","volume":"21","author":"Paolillo","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2021.12.027_bib0013","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2021.12.027_bib0014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative efficacy of spironolactone, eplerenone, and canrenone in patients with chronic heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2021.12.027_bib0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2021.12.027_bib0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ehf2.12244","article-title":"Mineralocorticoid receptor antagonists for heart failure: real-life observational study","volume":"5","author":"Bruno","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2021.12.027_bib0017","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.106.649426","article-title":"Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival","volume":"114","author":"Jankowska","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.12.027_bib0018","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0300-8932(10)70180-9","article-title":"Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro","volume":"63","author":"Sanchez-Mas","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.ejim.2021.12.027_bib0019","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521004374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521004374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:35:58Z","timestamp":1760607358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521004374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":19,"alternative-id":["S0953620521004374"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.12.027","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world comparison of spironolactone and eplerenone in patients with heart failure","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}